Parse Biosciences

Parse Biosciences is enabling the democratization of single-cell sequencing. Because of Evercode, our patented technique of combinatorial barcoding, researchers are able to profile up to one million cells at a time without the need for expensive lab equipment. The barrier to entry for single-cell sequencing needs to be lower– it needs to be more flexible, more scalable, and more affordable. Only then can we expand access to innovation across therapeutic areas like oncology, neurology, and immunology. At Parse Biosciences, we understand the difficulty researchers face in finding affordable technology that streamlines workflow, and are committed to providing them with the tools they need to improve human health.

Parse Biosciences is a Seattle-based company with the mission of accelerating progress in human health and scientific research. At the core of our company is our pioneering approach for single cell sequencing. Single-cell sequencing has already enabled groundbreaking discoveries which have led to new understandings of cancer treatment, tissue repair, stem cell therapy, kidney and liver disease, brain development and the immune system. At Parse Biosciences, we are providing researchers with the ability to perform single cell sequencing with unprecedented scale and ease.